The company says that its own market research has found that two out of three pet owners have at least one dog with bad breath, and 90% of owners try a single chew before deciding to buy a bag of 15.
The company also says that in addition to dealing with halitosis, the chews have been scientifically proven to reduce calculus and plaque when given daily1.
Product Manager Claire Lewis said: "We are delighted to be able to add VeggieDent FR3SH singles to the Virbac oral healthcare range. Single chews make a great addition to practice waiting rooms, but can also be a useful tool to promote oral care in consult and even during puppy parties.
VeggieDent FR3SH™ singles are available to order from the veterinary wholesalers now.
For more information, contact your Virbac Territory Manager.
Reference
Almost half of the vets that watched a webinar about ferret medicine have said they would change their treatment protocols for adrenal disease and reproduction management as a result of what they learned.
The Virbac-sponsored webinar was led by John Chitty BVetMed CertZooMed CBiol MSB MRCVS and viewed by more than 600 practices, making it the most popular CPD event hosted by The Webinar Vet this year.
John Chitty said: "I provided an overview of treatment protocols for all of the common diseases but focused on adrenal disease as it's highly prevalent in neutered ferrets but may be reduced by the routine use of deslorelin implants. These implants can also be used to avoid surgical neutering."
According to a post-webinar questionnaire, 33% of clinicians said that they saw ferrets more than five times a year. Chris Geddes MRCVS, Product Manager at Virbac said: "This confirms what we thought: ferrets are being presented more and more in practice and so education on this species is vital. An amazing 41% of respondents said that they would change their protocols for reproduction management and 40% their treatment of adrenal disease following the webinar, showing how useful it was to those attending."
Virbac recently announced that it has gained a marketing authorisation for the use of Suprelorin 9.4mg in male ferrets. Suprelorin, a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin, offers temporary sterilisation without the need for surgery.
For those who were unable to see it at the time, the webinar can now be viewed by visiting www.virbac.co.uk. A CPD certificate is also available for download as are six other webinars previously sponsored by Virbac.
This list was originally prepared BVDA President, Alex Smithson after being asked by lots of colleagues which dentistry CPD he knows of or recommends.
To his list, we've also added events hosted by Improve International and Bob Partridge.
In addition to the following courses, Orosurgeon Ltd provides in-house, group and individual training throughout the year. Courses can cover all dentistry and oral surgery topics, basic to advanced, including restorative & endodontic dentistry.
Contact admin@orosurgeon.co.uk for details.
VetSurgeon member Shailen Jasani MA VetMB MRCVS DipACVECC has launched the Ralph site (theralphsite.com), a website offering support and advice to those coping with pet bereavement.
The site contains forums, downloadable advice sheets, a directory of crematoria and cemeteries, and offers owners the ability to create a memorial for their pet.
The Ralph site was named after Shailen's own cat, which died after a car accident in 2010. Shailen funded the setup of the site, and it is a not-for-proft.
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
The two-day event, now in its fifth year, aims to combine world-class CPD for the whole practice team with an outdoor ‘festival’ atmosphere.
The organisers say that the wellbeing of veterinary professionals has always been a strong focus of VET Festival, but the inclusion of Lara Heimann in the Wellness and Practice Development lecture, takes it to a new level. Laura has developed her own vinyasa yoga style and regularly leads international retreats and workshops.
Speakers in the clinical programme will include:
Dr Antonio Pozzi, Head of the Clinic for Small Animal Surgery at the University of Zurich, Switzerland
Dr Susan Little, co-owner of two feline specialty practices in Ottawa, Canada, and past president of the American Association of Feline Practitioners
Dr Ronaldo da Costa, Professor in Neurology and Neurosurgery at Ohio State University, USA.
Veterinary cardiologist Professor John E Rush. A Diplomate of both the American Colleges of Veterinary Internal Medicine and Emergency and Critical Care, Dr Rush has been a professor for 25 years at the Cummings Veterinary Medicine Centre at Tufts University in Massachusetts
Behaviourist Dr Sarah Heath. A founding Diplomate of the European College of Animal Welfare and Behavioural Medicine
Soft-tissue surgeon Professor Christopher Adin. Professor Adin is Chair of the University of Florida’s Department of Small Animal Clinical Sciences and Associate Professor of Soft Tissue.
Veterinary nurses are welcome to attend any of the lectures, in addition to those in the dedicated nursing stream. An exhibition of the latest products and services for all veterinary professionals takes place in a dedicated arena.
Nicole Cooper, event director, said: "VET Festival is unique in bringing together cutting-edge, inspirational learning, fun and the great outdoors. CPD from our world-leading speakers is delivered in a high quality and contemporary setting but, once work is done, we encourage delegates to relax and enjoy free admission for them, their friends and family to the VETFest Live Party Night."
She added: "With the wellness and wellbeing of members of our profession increasingly in the spotlight, we’re delighted to welcome Lara Heimann for 2019 and hope that she will help our delegates to develop practical solutions to living healthier and more balanced lives."
Supported by MWI Animal Health, VET Festival also offers a 'Family Hub', a place where children can play whilst their parents listen to lectures.
Alan White Group Commercial Director at MWI Animal Health, said: "Balancing work and family life can often be a juggling act, particularly in the veterinary profession where time is in short supply. This can sometimes compromise the work-life balance of vets, nurses and other team members. At VET Festival, the 'Family Hub' means that there is no compromise and that both our attendees and their families can get the best out of their time with us."
You can buy tickets here: https://www.vetfestival.co.uk/delegate-info/ticket-information
Dr Bohnen faced two charges. The first was that in March 2017, she failed to attend to Belle, a Cavalier King Charles Spaniel, in order to provide appropriate and adequate care including: assisting Belle with urination, monitoring her with a view to considering alternative treatment options, and monitoring her with a view to providing her owners with an update on her condition.
The second charge was that Dr Bohnen later claimed dishonestly that she had attended to the animal, both to the owners, in clinical records hospital records, in a note provided to colleagues and during internal disciplinary proceedings held at her practice.
At the outset of the hearing the Committee considered an application from Dr Bohnen for the hearing to be postponed as she was now based in her home country of South Africa, and said she could not apply for a visa to return to the UK until later in the year and internet access in her location was poor.
However, the Committee found that the RCVS had properly served the notice of inquiry to Dr Bohnen in accordance with the current rules, that she had had sufficient time and opportunity to apply for a visa since receiving the notice and that, in any case, she could remotely ‘attend’ the hearing via Skype or telephone if necessary by travelling to somewhere that did have adequate internet connectivity, and so it refused the application.
The Disciplinary Committee then considered the facts of the case and heard evidence from the owners of Belle, the clinical director of the practice that Dr Bohnen worked in at the relevant time and a veterinary nurse, who was a student doing her training at the practice during the time of the events in question.
Having considered all of the evidence, the Committee dismissed the parts of the first charge relating to considering alternative treatment options and updating the owners in relation to Belle’s condition. They did, however, find the charge proven in relation to Dr Bohnen failing to assist Belle with urination.
The Committee found all aspects of the second charge proven in its entirety after Dr Bohnen admitted in advance of the hearing, that her representations were false and misleading.
The Committee then went on to consider whether the second charge and the aspects of the first charge that were found proven amounted to serious professional misconduct both individually and cumulatively.
The Committee considered that Dr Bohnen’s conduct in failing to assist Belle with urination, whilst falling below the standard to be expected of a reasonably competent veterinary surgeon, did not amount to serious professional misconduct.
The Committee did however find that Dr Bohnen’s conduct with regards to the second charge constituted serious professional misconduct.
Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considers that the respondent’s dishonesty was the prime aggravating factor in this case. Although overall it could be regarded as a single incident, the Committee has found that it involved the fabrication of a number of notes and clinical records in the immediate aftermath of the death of the dog, but, thereafter, the respondent continued to deny the falsity of the fabricated records that she had created up to and until the conclusion of her interview by the practice on 30 March 2017.
"During that time, the respondent had contacted the alarm company responsible for the security of the premises of the practice, to enquire whether the security system would record the times of the alarm being switched on and off. This indicated that the respondent’s dishonesty continued over a significant period of time, and that her persistence in sticking to her story became premeditated. In other words, the respondent’s conduct over this time indicated a clear attempt to deceive."
Regarding the sanction for Dr Bohnen, the Committee considered that the principle aggravating factors in the case were serious dishonesty towards both her colleagues and the owners of the dog and involved clear breaches of the Code of Professional Conduct. By way of mitigation, the Committee noted that Dr Bohnen is of previous good character with no other professional findings against her and that she had demonstrated some insight into her behaviour and had admitted being dishonest and misleading prior to the hearing.
Summing up, Professor Barr said: "Because of the seriousness of this case, the Committee did not consider that it was appropriate to postpone judgement, take no further action, or to administer a reprimand and warning as to future conduct. The Committee considered that the respondent’s conduct, involving significant and admitted dishonesty over a period of time, required a significant penalty, in order to protect the welfare of animals and to serve the public interest.
"Accordingly, the Committee has decided to direct that the respondent’s registration be suspended for a period of nine months."
Dr Bohnen has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.
Whilst you're here, take a moment to see our latest job opportunities for vets.
According to Davies, Sharpsmart is the world’s safest and most environmentally responsible sharps and clinical waste management system, proven to:
Ellie West, anaesthetist at Davies and Green Group leader said: "We are really excited to have the opportunity to be the first veterinary centre to be working with Sharpsmart and are already seeing great results in carbon reduction and we look forward to sharing our results later in 2019."
Adrian Giles, Total Waste Program Manager for Sharpsmart added: "Working with Davies has enabled us to showcase our safety engineered sharps system in a new and exciting arena where sharps safety and sustainability are a priority.
"The transition to Sharpsmart was seamless and was completed across the centre in a day without any challenges. Face-to-face training was provided to staff along with touch point education material. We look forward to strengthening our partnership with Davies over the coming months and years."
As part of its green drive, Davies will be hosting 'Sustainability CPD' for referring vets on May 2nd 2019 at its HQ in Higham Gobion, Hertforshire.
Ellie West said: "Run by the Sustainability Leads at DVS, this evening aims to increase your carbon literacy, explore the challenges and barriers to improving sustainability in your daily practice and find some positive solutions to implement sustainability. The challenges which we have faced at DVS will be explored, along with the co-benefits of sustainability to our business, and useful resources to help your practice to be more environmentally friendly and resilient will be highlighted."
You can book your place here https://vetspecialists.co.uk/events/davies-first-sustainability-cpd-for-referring-vets/ or contact Ellie.West@vetspecialists.co.uk if you are interested in attending or would like more information.
Davies has also produced a suite of Waste Segregation Posters which are proving popular with their referring practices. You can find out more and view the posters here https://vetspecialists.co.uk/sustainability/sustainability-initiatives-at-davies-your-questions-answered/.
For more information or to receive print ready PDFs, contact marketing@vetspecialists.co.uk
Rabbits are the third most commonly anaesthetised pet in the UK, however they have a seven times greater overall risk of perioperative death than dogs1.
Jurox says Alfaxan 10mg/ml solution for injection provides a wide safety margin, an excellent cardio-respiratory profile and is dosed to effect, making it an excellent choice for the anaesthetic induction of rabbits.
The company also says Alfaxan provides smooth and rapid induction and recovery, painless administration and good muscle relaxation with low impact on ventilation and blood pressure.
Richard Beckwith, country manager of Jurox (UK) Ltd said: "Rabbits are a growing pet population and increasingly play a more important part in UK vet practices, which is why Jurox has invested in research in this species.
"We are happy we can now support our vet and nurse clients by providing a new and reliable choice for induction of anaesthesia in pet rabbits that has been extensively trialed and researched.
"Alfaxan is a very versatile product as it is convenient for any type of situation, whether it is surgery on healthy animals or high risk patients such as pet rabbits. With Alfaxan we hope to make a contribution to the future of veterinary anaesthesia in the UK and are confident our clients will be able to deliver the best practice anaesthesia they believe in."
For more information, visit: Alfaxan.co.uk. Alternatively, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
References
The drug monographs for both formularies were revised and updated by the editorial panels in 2022, so the new edition contains the most up-to-date information about the medications used for dogs, cats and exotic pets.
The new formularies contain new drugs, new drug monographs, updated antimicrobial guidelines, parasiticide guidelines and sedation protocols.
The new formularies are available to buy at the BSAVA Publications stand at Congress, with a special 20% Congress discount.
Eligible members who are attending Congress can collect their copy of the BSAVA Small Animal Formulary, 11th edition – Part A: Canine and Feline from the Exhibition Hall.
Any eligible members who are not going to BSAVA Congress will be sent their printed copy from April 2023 onwards.
Eligible members will be sent their printed copy of the BSAVA Small Animal Formulary, 11th edition – Part B: Exotic Pets from April 2023 onwards.
All BSAVA members have access to the online version via the BSAVA Library and the BSAVA app.
Both Part A and Part B are available in print from www.bsava.com/shop (£55; £35.75 to BSAVA members), or as part of a 12-month digital subscription from www.bsavalibrary.com/formulary with Part A: Canine and Feline, Part B: Exotic Pets and the client information leaflets (£256 + VAT; free to BSAVA members).
Veterinary Review and Practice Heart magazines have ceased publication.
The former was first launched 15 years ago by John Alborough, and sold to Onstream Communications in May 2007.
Mark Johnston, Managing Director of Onstream Communications said: "It wasn't commercially viable running a full publishing team for two magazines, especially in the current economic environment, so we're consolidating our activities and concentrating on electronic media".
These include the peer-reviewed online clinical information services: Canis, Felis, Equis and Lapis and the provision of websites for veterinary practices and companies wishing to promote themselves and their products and services.
The company says that of the 249 responses to its Puppy Tooth Census received so far (of which 40% were from vets, 21% vet nurses, 2% other veterinary professionals and 37% puppy owners), 25% were poodle crosses.
This, says the company, is in line with anecdotal reports that vets are seeing more dental conditions in poodle cross puppies.
VisioCare is now calling for more vets to take part in the survey at https://bit.ly/Visiocare_PuppyToothCensus.
With very few studies that address dental disease in puppies and a lack of current data, it is hoped that the survey will advance understanding and improve oral health and welfare.
Every veterinary respondent will be given access to a pack of educational materials to use in the consulting room, including digital animations and dental images that can be used to enhance client communication around the topic, together with explainer videos and puppy owner fact sheets and leaflets.
In addition, each month for the next three months, all responses will be entered into a prize draw for the chance to win a £50 John Lewis gift voucher.
VisioCare is also offering a free webinar: "Challenges in Puppy Dentistry and Malocclusion" presented by Ingrid Tundo, Head of the Dentistry and Oral Surgery Department at the Royal (Dick) Vet School, viewable at: https://veterinarywebinars.com/register/puppy-dentistry-malocclusion.
Finally, Nicky Diver-Clarke, Marketing Manager at VisioCare Services is also offering a free marketing CPD session for practices that want to find the best way to amplify awareness of the Puppy Tooth Census within their practice.
Anyone interested in accessing the free support can contact her at nicky@visiocareservices.co.uk.
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.
Elanco Companion Animal Health - maker of Comfortis, the flea treatment for dogs - is hosting an online evening webinar on Tuesday 10th January to highlight what pet owners want from their vets.
The free webinar follows research into the perceptions of clients and veterinary surgeons as to what attributes constitute a 'good vet'1. According to Elanco, the research revealed a distinct mismatch between what vets think and what pet owners think. The webinar will highlight these differences and the steps veterinary professionals can take to address them. Additionally, it will provide veterinary professionals with the opportunity to learn more about Comfortis and ask questions of Elanco's technical consultants.
Presented by Alan Robinson BVSc MRCVS DMS, a business development consultant for independent veterinary practices, the webinar will start at 8.00pm and will account for two hours CPD. Veterinary surgeons and nurses wishing to book a place should visit www.thewebinarvet.com/comfortis.
For further information, please telephone 01256 353131, email elancoCAH.uk@lilly.com or contact your local Elanco key account manager.
According to the company, it's the first large-scale EMS online booking system of its type in the veterinary profession and it will mean students can find practice placements at the touch of a button, instead of having to spend time contacting individual surgeries.
With the new system, the 200 CVS practices which currently offer EMS have their own page, where information is provided about the practice, along with a list of available placements.
Once registered, students can search for placements by practice name, location and date.
When a student finds a suitable placement a booking request is triggered, connecting the student to the host practice so that the booking can be confirmed.
CVS has also created a new EMS support framework, based on the RCVS day one competencies, to help practices and students structure each placement.
The company says the new framework puts health, wellbeing and professional skills on a par with clinical skills, to encourage students to take a holistic approach to their development - helping them to grow into happy, competent and confident veterinary surgeons.
Nigel Stansbie, Head of Online Course Creation at CVS, said: “As a major employer within the industry, we are fully committed to supporting the education and development of vet students, by offering high-quality EMS placements, to help them gain the skills and knowledge they will need to thrive when they join the workforce.
“Though we know that there is current debate about the future EMS requirements, we recognise the importance of EMS and are confident that the support we have put in place will enable students to make the most of these valuable work experience opportunties.”
The new CVS EMS online booking system is hosted on the company's knowledge hub: https://www.cvs-knowledgehub.com/.
Results for the 2010 RCVS Council elections have been released today and, following a slight increase in turnout for the second year running, four existing Council Members and one former Member have been returned for another four years. However, new to Council this year and securing the most votes was Preston-based veterinary practitioner David Catlow.
4,232 veterinary surgeons out of a possible 22,541 cast their votes this year, an increase of 0.6% from 18.2% in 2009. The results of the voting are as follows:
CATLOW, David Frederick. 2,383. Elected. TAPSFIELD-WRIGHT. Clare Joan. 2,352. Elected.SHIELD, Christine Fiona. 2,133. Elected.MOLYNEUX, Jacqueline Rosina. 2,111. Elected.SMITH, Neil Christopher. 2,089. Elected.PARTRIDGE, Robert Duncan. 1,971. Elected.NELL, Adi. 1,781. ANDERSON, Roy Paxton. 1,455. GODDARD, Philip Campbell. 1,385. LONSDALE, Thomas, 380.
Terms of office for the six successful candidates will (re)commence at RCVS Day on 2 July 2010.
Following a successful partnership last year, the RCVS again teamed up with this website to allow voters more opportunity to quiz the candidates directly and find out more about their views.
Once again, this seemed to prove popular with the electorate although it presented candidates with a large increase in their workload during the voting period. Page views in the election section rose 23% to 28,347 this year; 48 discussion threads were started (slightly down from 53) and total responses rose dramatically by 47% to 988.
A new incentive for members to vote this year was a pledge to donate 20p per voter to the DEC Haiti Earthquake Appeal. A donation of just over £845 will therefore be made shortly.
RCVS Registrar Jane Hern said: "An increase in turnout, if only a small one, is to be welcomed and I hope we can continue to increase members' interest in the composition and activities of RCVS Council. I'd like to thank all ten candidates who stood for election this year; my congratulations to those elected and my commiserations to those who weren't successful this time."
Note: there was no VN Council election this year as only two nominations were received for the two available places. These will be filled by Suzanne May RVN and Hilary Orpet RVN.
Being an intranasal vaccine, Bovalto Respi IN triggers mucosal immunity in the nasal passages and throat area. It can be delivered from 10 days of age without the need for a booster and provides immunity for 12 weeks, from 10 days after vaccination.
Boehringer says it has also been shown to be effective in the face of MDA (maternally derived antibodies).
The new bottle now has a wider neck, which apparently makes for a better fit with the accompanying Respisafe applicator and nozzle.
Brand manager Matt Yarnall said: "The Respisafe applicator ensures that vaccination is a comfortable process for both farmer and calf and the improved fit will make the job even easier.
"With an intranasal vaccine, it is important that the vaccine droplets coat the mucosa of the nasal passages, where they can begin to work. If they are too big, then the vaccine can run out of the nose, and if too small then the droplets are carried into the lungs and are wasted. The Respisafe system ensures that the optimum size of droplet is administered to the right place in an efficient and easy way.”
Bovalto Respi Intranasal protects against the two main respiratory viruses – RSV and PI3, and during its development it was tested against current strains, that are associated with causing disease in cattle1.
Stock of the new bottles will start to enter circulation with vets from mid-July, with an expectation that the existing version will still be in circulation until early in the new year.
The programme offers a structured and heavily supported first year in practice, including hands-on surgical training and seminars from Advanced Veterinary Practitioners, at the Pets'n'Vets' Roundhouse Veterinary Hospital in Glasgow.
Totally Grad! also includes a mentor plan and additional monthly benchmarking and seminars and support.
Oliver Jackson, partner at Pets'n'Vets said: "We are well aware that many larger veterinary entities run new graduate programmes and we are proud to say that Totally Grad! offers great advantages that come with our independent structure.
"Independent practice can offer a rewarding working environment for new graduates – particularly progressive practices such as ours. We can offer new graduates not only the close-knit, friendly, helpful, stable, first-opinion experience, but also provide opportunities for career growth and development.
"We have the facility for graduates to explore their particular areas of interest. Indeed, in our practice it is possible for a new graduate to change our way of working – the decision-makers are available and listening. We now have many vets working with us who have come through the practice from our graduate system and who have gone on to help shape our practice.
"The success of our Laparoscopic and Cardiology clinics can be attributed to those vets, as can various other client service initiatives and ways of working. New blood brings new ideas and we welcome that."
Totally Grad! will also be open to fellow independent practices.
Oliver added: "By opening up our Totally Grad! programme, we are offering a simple, accessible facility to those fellow independent practices able and willing to provide a mentor and allow their graduate vets to be out of their practice for one or two days per month over a 12 month period. It fits perfectly with our Roundhouse Referrals offering which offers advice, CPD and support to local practices."
Any independent practices interested in participating in the programme can contact oliver.jackson@petsnvets.org while final year students interested in learning more about the programme can visit the website at www.totallygrad.co.uk and/or email Karen W at hello@totallygrad.co.uk
Dechra Veterinary Products has launched Anesketin, an anaesthetic licensed for cats, dogs and horses.
Anesketin contains ketamine 100mg/ml solution for injection and is indicated for induction of anaesthesia. In cats, it can also be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required.
Dechra Brand Manager Carol Morgan said: "Anesketin is a versatile product which can be used as a sole agent in cats or in combination with appropriate sedatives and analgesics in cats, dogs and horses for induction and maintenance of anaesthesia.
Anesketin is available in 10 ml vials. The withdrawal period for meat, offal and milk is one day and the product does not require any special storage conditions.
For further information, visit www.dechra.co.uk
This only affects batch number C967336A, expires before 07/2020. Any other batches of Tylan 200 Injection are not affected and may continue to be distributed.
Elanco is contacting wholesale dealers and veterinary surgeons to examine inventory immediately and quarantine products subject to this recall.
For further information regarding the recall, please contact Ms Victoria Haslingden 01256 779519 or email elanco_orders@lilly.com
The re-categorisation means veterinary practices can sell the topical parasiticides to ‘walk-in clients’ without the need of a prescription.
Andrew Fullerton, veterinary surgeon and product manager at Ceva Animal Health, said: “The new NFA-VPS category for Vectra 3D spot-on solution for dogs and Vectra Felis 423mg/42.3mg spot-on solution for cats provides veterinary practices with greater flexibility to sell easy-to-use, fast and effective parasite prevention and treatment without a prescription."
For more information, contact your Ceva Animal Health account manager or email cevauk@ceva.com.
Tulaven is licensed for the treatment and metaphylaxis of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis.
Tulaven can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
Tulaven is also is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.
Ceva highlights that Tulaven is the only tulathromycin available in CLAS (Ceva Layered Anti Shatter) vials1, which have less impact on the environment2, are easier to handle3 and transport4, and are preferred by farmers5.
Cuneyt Seckin, Managing Director of Ceva Animal Health, said: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of Tulaven is the next addition to this range, enabling us to offer even more support to vets and farmers.”
For further information, contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
Amflee Combo, a POM, is being launched by a newcomer to the UK market, a Slovenian company called Krka (pronounced kirka). The company says it plans to introduce a vast range of small and production animal products onto the UK market in the next few years.
Killian Gaffney, Head of sales and marketing at Krka, says the company intends to support UK veterinary surgeons by offering high quality products and by building business relationships that will help protect veterinary incomes, at the same time as offering good value to their customers.
Killian said: "Amflee Combo has some unique features that we believe will set it apart from the competition. We know the combination of the two active ingredients in Amflee Combo is very effective for the treatment of fleas, ticks and biting lice and as part of a treatment strategy for flea allergy dermatitis in dogs and cats. S-methoprene is also effective against flea eggs and larvae in the environment.
"However, these ingredients can be susceptible to degradation when subjected to light and moisture, which is why each Amflee Combo pipette comes in its own special foil wrapper. The pipettes have also been designed for convenience of use, since we know that only 22% of owners apply spot-ons correctly1."
A range of product and client literature to support the use of Amflee Combo is available by calling 01753 722 150.
Amflee Combo is available in a variety of packs for cats and different sized dogs, containing either three or six pipettes. The recommended treatment is one pipette every four weeks.
Further information about Amflee Combo or Krka is available at www.krka.co.uk
1 El veterinario ante el cambio climatico Argos 107, 2010.
The Pitpat was designed in Cambridge, launched in 2016 and is now the leading dog activity monitor on the market, with over 50,000 sold.
I was invited to review the Pitpat by one of the company's non-executive directors, Myra Forster-van Hijfte FRCVS, a European and RCVS Specialist in Small Animal Medicine who was also one of the angel investors.
I wasn't convinced that this was something every dog owner would want to use regularly. You'd have to be a bit obsessed to be routinely reviewing the activity levels of a perfectly fit young dog. But I think there is real potential for it to add value to veterinary nurses' obesity clinics and also to measure a response to treatment for things like osteoarthritis (OA). As such, it is perhaps something for practices to consider buying for themselves, and then loaning it out to the owners of dogs on a weight loss programme or which are getting treatment for OA.
Myra said: "PitPat gives an objective measurement of the actual activity the dog has done and the app gives the owner tailored advice (based on breed, age and sex of the dog) on how much exercise their dog should be doing and an estimate of daily calories their dog has burnt. This will help owners keep their dogs fit and healthy and in the correct body condition.
"PitPat is useful in weight management clinics by improving owner engagement through the associated weight app. Encouraging exercise also provides the owner with a positive contribution towards weight management.
"Monitoring activity pre- and post treatment, for instance dogs with osteoarthritis on NSAID's, provides vet and owner with an objective measure of whether treatment is effective or not."
You can watch the full review here. If you're interested in technology that is designed to make life easier, do subscribe to the channel!
For more information about Pitpat, visit: https://www.pitpat.com/. Veterinary practices that want to buy a Pitpat for use with their clients will get a trade discount. Contact the company for more details.
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.